Improvement in severe asthma patients receiving biologics and factors associated with persistent insufficient control: a real-life national study
Therapeutic Advances in Respiratory Disease · 2023
DOI: 10.1177/17534666231202749 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Therapeutic Advances in Respiratory Disease, 2023. Verfasst von Laurent Guilleminault und 34 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Faculty of Medicine, Toulouse University Hospital Centre, 24 chemin de Pouvourville, Toulouse 31059, France. Hauptthemen laut MEDLINE: Anti-Asthmatic Agents, Asthma, Biological Products, Gastroesophageal Reflux. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AstraZeneca France.
Abstract (Originalsprache)
Background
Biological therapies have revolutionized the treatment of severe asthma with type 2 inflammation. Although such treatments are very effective in reducing exacerbation and the dose of oral steroids, little is known about the persistence of symptoms in severe asthma patients treated with biologics.
Purpose
We aim to describe asthma control and healthcare consumption of severe asthma patients treated with biologics.
Design
The Second Souffle study is a real-life prospective observational study endorsed by the Clinical Research Initiative in Severe Asthma: a Lever for Innovation & Science Network.
Methods
Adults with a confirmed diagnosis of severe asthma for at least 12 months’ duration were enrolled in the study. A self-administered questionnaire including the Asthma Control Questionnaire (ACQ), Asthma Quality of Life Questionnaire (AQLQ) and a compliance evaluation test was given to the patients. Healthcare consumption within 12 months prior to enrolment was documented. In patients receiving biologics, doctors indicated whether the patients were biologic responders or non-responders.
Results
The characteristics of 431 patients with severe asthma were analysed. Among them, 409 patients (94.9%) presented asthma with type 2 inflammation (T2 high) profile, and 297 (72.6%) patients with a T2 high phenotype were treated with a biologic. Physicians estimated that 88.2% of patients receiving biologics were responders. However, asthma control was only achieved in 25.3% of those patients (ACQ > 0.75). A high proportion of patients (77.8%) identified as responders to biologics were not controlled according to the ACQ score. About 50% of patients continue to use oral corticosteroids either daily (25.2%) or more than three times a year for at least three consecutive days (25.6%). Gastro-oesophageal Reflux Disease (GERD) and Obstructive Sleep Apnoea syndrome (OSA) were identified as independent factors associated with uncontrolled asthma.
Conclusion
Although a high proportion of severe asthma patients respond to biologics, only 25.3% have controlled asthma. GERD and OSA are independent factors of uncontrolled asthma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory Medicine, Faculty of Medicine, Toulouse University Hospital Centre, 24 chemin de Pouvourville, Toulouse 31059, France.
- Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), Inserm U1291, University of Toulouse, CNRS U5282, Toulouse, France.
- CRISALIS/F-CRIN INSERM Network, Toulouse, France.
- University of French West Indies, Respiratory Diseases Department, Pointe -à Pitre, Guadeloupe.
- AstraZeneca, Paris, France.
- Respiratory Diseases Department, Montpellier University Hospital, Montpellier, France.
ORCID-Profile: Laurent Guilleminault
Förderung
- AstraZeneca France
Zitieren
APA
Guilleminault, L., Camus, C., Raherison-Semjen, C., Capdepon, A., Bourdin, A., Bonniaud, P., Fry, S., Devouassoux, G., Blanc, F. X., Pison, C., Dupin, C., Khayath, N., Courdeau, J., Valcke-Brossollet, J., Nocent-Ejnaini, C., Rolland, F., Lamandi, C., Proust, A., Ozier, A., …, & Didier, A. (2023). Improvement in severe asthma patients receiving biologics and factors associated with persistent insufficient control: a real-life national study. Therapeutic Advances in Respiratory Disease. https://doi.org/10.1177/17534666231202749
Vancouver
Guilleminault L, Camus C, Raherison-Semjen C, Capdepon A, Bourdin A, Bonniaud P, et al. Improvement in severe asthma patients receiving biologics and factors associated with persistent insufficient control: a real-life national study. Therapeutic Advances in Respiratory Disease. 2023. doi:10.1177/17534666231202749
BibTeX
@article{Guilleminault2023,
author = {Guilleminault, Laurent and Camus, Claire and Raherison-Semjen, Chantal and Capdepon, Audrey and Bourdin, Arnaud and Bonniaud, Philippe and Fry, Stéphanie and Devouassoux, Gilles and Blanc, François-Xavier and Pison, Christophe and Dupin, Clairelyne and Khayath, Naji and Courdeau, Joelle and Valcke-Brossollet, Judith and Nocent-Ejnaini, Cécilia and Rolland, Fabien and Lamandi, Carmen and Proust, Alain and Ozier, Anaig and Portel, Laurent and Gaspard, Wanda and Roux-Claude, Pauline and Beurnier, Antoine and Martinez, Stéphanie and Dot, Jean-Marc and Hennegrave, Florence and Vignal, Guillaume and Auvray, Etienne and Paleiron, Nicolas and Just, Nicolas and Miltgen, Jean and Russier, Maud and Olivier, Cécile and Taillé, Camille and Didier, Alain},
title = {Improvement in severe asthma patients receiving biologics and factors associated with persistent insufficient control: a real-life national study},
journal = {Therapeutic Advances in Respiratory Disease},
year = {2023},
doi = {10.1177/17534666231202749}
}
EUVIMED